Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people who lose weight on Mounjaro begin to see changes within the first four weeks, though meaningful reductions in body weight typically build over several months as the dose increases. In the SURMOUNT-1 trial, participants on the highest dose lost an average of around 20–21% of their body weight over 72 weeks. Mounjaro (tirzepatide) is a prescription-only medicine; a GPhC-registered prescriber assesses whether it is suitable for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Treatment begins at 2.5mg. That starting dose exists to let your digestive system settle; nausea and other GI symptoms are most likely to appear early, and a lower dose reduces the chance they derail you before you've begun. It would be unrealistic to expect dramatic weight loss at this stage, and patients who tell our prescribers they're disappointed at week four almost always go on to see much stronger results as the dose climbs.
Some people do notice a modest drop in the first month, appetite falls, portion sizes shrink naturally, and a small reduction in calorie intake adds up quickly. If you want a clearer sense of how quickly you will lose weight on Mounjaro, including what a realistic first month looks like, that page sets out the detail. The NHS medicines page for tirzepatide is a useful reference for what to expect in these early weeks and how to manage early side effects.
The key thing to understand at this step is that how quickly Mounjaro works for weight loss is partly a function of how steadily doses increase, and that is a clinical decision, not something to rush.
From 2.5mg the prescriber titrates upward, typically in four-week steps through 5mg, 7.5mg and beyond, as your body tolerates each level. This is the phase where most people begin to feel the fuller effect of the medicine. Appetite suppression becomes more consistent, the feeling of fullness after smaller meals deepens, and weight loss tends to accelerate.
A question our prescribers hear most weeks is whether it's safe to move up a dose faster than planned. The answer is that the titration schedule is evidence-based, it balances effectiveness against tolerability, and jumping ahead raises the risk of GI side effects that can make continuing the treatment harder.
By the end of month six, people on effective doses often report weight reductions of 8–12% or more, though again individual results vary. For context on the full duration of treatment and what happens beyond six months, the evidence on how long people typically stay on Mounjaro is worth reading alongside this.
The SURMOUNT-1 trial, published in the New England Journal of Medicine, ran for 72 weeks. At the 15mg maintenance dose, average body-weight reduction was around 20–21%, representing real, sustained loss for thousands of adults, not a quick fix.
The weight-loss curve in these trials is not linear. Progress tends to plateau briefly after each dose step and then resume. By month twelve, many participants at therapeutic doses had lost a substantial proportion of their eventual total. The final months of the trial saw slower additional loss as participants approached a new stable weight, which is biologically normal and not a sign the medicine has stopped working.
Starting weight matters here too. Someone beginning treatment at a higher BMI will often lose more total kilograms even if the percentage is similar to someone with a lower starting weight. For a detailed look at how quickly you lose weight on tirzepatide, including how the timeline can vary by individual factors, that page covers this in more depth.
If you're thinking about what Mounjaro costs as part of a longer treatment course, our Mounjaro pricing page sets out what a private prescription actually includes.
The clinical trials establish population averages. Your actual rate of loss depends on several factors: the highest dose you tolerate and reach, how consistently you take the medicine, the dietary changes you make alongside it, your activity levels, and underlying health conditions. NICE's appraisal of tirzepatide (TA1026) notes that continuing treatment beyond six months is reviewed if weight loss at the highest tolerated dose has been less than 5%, a threshold that puts the evidence in a practical clinical context.
Sleep, stress and hormonal factors also influence how quickly weight changes. Mounjaro is not a passive intervention; people who make even modest adjustments to food choices alongside it tend to see faster progress than those who change nothing. That said, the medicine's effect on appetite is significant enough that many people find those adjustments feel easier than previous attempts without it.
To explore the broader picture of Mounjaro as a treatment (mechanism, eligibility, side effects and the clinical evidence) the Mounjaro treatment overview brings all of that together. And if you're ready to find out whether it could be right for you, starting a free consultation puts your case in front of a GPhC-registered prescriber the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.